Market Overview:
Chronic Immune Thrombocytopenia (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes, causing a decrease in platelet production.

Market Dynamics:
Growing demand for therapeutics for the treatment of rare blood related disorders, and increasing number of products approved by the Food and Drug Administration are some of the major factors driving the growth of the chronic immune thrombocytopenia (ITP) market globally. According to National Organization of Rare Disorders (NORD), the incidence of ITP among adults in the USA is estimated to be 3.3 per 100,000 adults/year. The prevalence is 9.5 cases per 100,000. The incidence of ITP increases with age and is more common over the age of 60. Among adults (age 30-60) diagnosed with chronic ITP, there are 2.6 cases among women for every case involving a male.

However, despite the increasing use of Thrombopoietin Receptor Agonist (TPO-RA), many patients remain refractory to available treatments. Current research is focused on combining therapies to address multiple mechanisms of disease simultaneously which may result into which may result into improved response rates and less toxicity.

Download free Report Sample: https://www.datamintelligence.com/download-sample/chronic-immune-thrombocytopenia-market

Market Segmentation:
On the basis of drug class, the Chronic Immune Thrombocytopenia Market is segmented into Immunoglobulin, Thrombopoetin (TPO) Receptor Agonist, Steroids, Platlet Stimulating Agents, and others. Among these, Steroids holds significant market share in 2018 and estimated to grow at a CAGR of 5.74% during the forecast period. There are two main types of steroids: corticosteroids and anabolic-androgenic steroids (or anabolics for short). Corticosteroid drugs, like prednisone, are the standard initial treatment for patients with immune thrombocytopenia ITP.

Chronic ITP is cured either when the platelet count falls below 30,000, or when there is bleeding. A steroid (such as prednisone) is the first treatment; if steroids do not keep the platelet count above 50,000, then it is treated with intravenous gamma globulin. If these treatments are not effective and the platelet count remains dangerously low or there is bleeding, other options such as removal of the spleen (splenectomy), treatment with rituximab (Rituxan), Romiplostim (Nplate) or Eltrombopag (Promacta, Revolade) are preferred.

Geographical Analysis:
North America holds the dominant market share for Chronic Immune Thrombocytopenia in 2018, and it is expected to maintain the growth over the forecast period, owing to the rising prevalence of immune thrombocytopenia, availability of treatment options and existence of effective reimbursement policies. According to the National Organization for Rare Disorders (NORD), the prevalence of immune thrombocytopenia among adults in the US is estimated to be 3.3 per 100,000 adults/year. In the United States, an estimated 30,000 new cases of ITP are diagnosed each year. Approximately 70% of adults with ITP are women, and 70 percent of these women are under the age of 40 when diagnosed.

The Europe Chronic ITP market is also growing at a significant CAGR during the forecast period, due to increasing cases of chronic ITP coupled with rising research activities for the treatment of chronic ITP. The European Medicines Agency (EMEA) has recognized chronic immune thrombocytopenia (ITP) as an orphan disease, with nearly 50,000 adult patients with chronic ITP in the European Union.

Competitive Analysis:
Some of the major players in the chronic immune thrombocytopenia market are: Novartis AG, Dova Pharmaceuticals, F.Hoffmann-La Roche Ltd., CSL Limited, Amgen Inc., Kyowa Hakko Kirin Co., Ltd., Shionogi Inc., Rigel Pharmaceuticals, Inc., Jiangsu Hengrui Pharmaceutical Co., Ltd., and Shire and Ligand Pharmaceuticals, Inc.

View Full Report Sample: https://www.datamintelligence.com/research-report/chronic-immune-thrombocytopenia-market

About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.

For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com